JP2021506815A - 界面活性ペプチドナノ構造および薬物送達における使用 - Google Patents

界面活性ペプチドナノ構造および薬物送達における使用 Download PDF

Info

Publication number
JP2021506815A
JP2021506815A JP2020532820A JP2020532820A JP2021506815A JP 2021506815 A JP2021506815 A JP 2021506815A JP 2020532820 A JP2020532820 A JP 2020532820A JP 2020532820 A JP2020532820 A JP 2020532820A JP 2021506815 A JP2021506815 A JP 2021506815A
Authority
JP
Japan
Prior art keywords
peptide
amino acid
composition
amino acids
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020532820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506815A5 (cg-RX-API-DMAC7.html
Inventor
ユン ソク ギル,
ユン ソク ギル,
エルトン アレスキ,
エルトン アレスキ,
範昭 松田
範昭 松田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3D Matrix Ltd
Original Assignee
3D Matrix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3D Matrix Ltd filed Critical 3D Matrix Ltd
Publication of JP2021506815A publication Critical patent/JP2021506815A/ja
Publication of JP2021506815A5 publication Critical patent/JP2021506815A5/ja
Priority to JP2023062404A priority Critical patent/JP7760174B2/ja
Priority to JP2024204161A priority patent/JP2025028940A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020532820A 2017-12-15 2018-11-30 界面活性ペプチドナノ構造および薬物送達における使用 Pending JP2021506815A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023062404A JP7760174B2 (ja) 2017-12-15 2023-04-06 界面活性ペプチドナノ構造および薬物送達における使用
JP2024204161A JP2025028940A (ja) 2017-12-15 2024-11-22 界面活性ペプチドナノ構造および薬物送達における使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762599566P 2017-12-15 2017-12-15
US62/599,566 2017-12-15
PCT/IB2018/001511 WO2019116092A1 (en) 2017-12-15 2018-11-30 Surfactant peptide nanostructures and uses in drug delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023062404A Division JP7760174B2 (ja) 2017-12-15 2023-04-06 界面活性ペプチドナノ構造および薬物送達における使用

Publications (2)

Publication Number Publication Date
JP2021506815A true JP2021506815A (ja) 2021-02-22
JP2021506815A5 JP2021506815A5 (cg-RX-API-DMAC7.html) 2022-01-06

Family

ID=65276214

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020532820A Pending JP2021506815A (ja) 2017-12-15 2018-11-30 界面活性ペプチドナノ構造および薬物送達における使用
JP2023062404A Active JP7760174B2 (ja) 2017-12-15 2023-04-06 界面活性ペプチドナノ構造および薬物送達における使用
JP2024204161A Pending JP2025028940A (ja) 2017-12-15 2024-11-22 界面活性ペプチドナノ構造および薬物送達における使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023062404A Active JP7760174B2 (ja) 2017-12-15 2023-04-06 界面活性ペプチドナノ構造および薬物送達における使用
JP2024204161A Pending JP2025028940A (ja) 2017-12-15 2024-11-22 界面活性ペプチドナノ構造および薬物送達における使用

Country Status (6)

Country Link
US (2) US11324703B2 (cg-RX-API-DMAC7.html)
EP (1) EP3723726A1 (cg-RX-API-DMAC7.html)
JP (3) JP2021506815A (cg-RX-API-DMAC7.html)
CN (2) CN117085140A (cg-RX-API-DMAC7.html)
IL (1) IL275380A (cg-RX-API-DMAC7.html)
WO (1) WO2019116092A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117085140A (zh) 2017-12-15 2023-11-21 立美基股份有限公司 表面活性剂肽纳米结构及在药物递送中的用途
EP3754336B1 (en) * 2018-02-15 2024-01-17 3-D Matrix, Ltd. Cancer lesion tissue evaluation for optimizing effect of boron neutron capture therapy
AU2022358487A1 (en) * 2021-09-30 2024-03-28 Protinhi B.V. Protease inhibitors

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582640A (en) 1982-03-08 1986-04-15 Collagen Corporation Injectable cross-linked collagen implant material
US4466641A (en) 1982-08-04 1984-08-21 The Lockformer Company Duct connecting system
US4642117A (en) 1985-03-22 1987-02-10 Collagen Corporation Mechanically sheared collagen implant material and method
US4947840A (en) 1987-08-21 1990-08-14 Massachusetts Institute Of Technology Biodegradable templates for the regeneration of tissues
US5236903A (en) 1988-06-24 1993-08-17 Ichiro Azuma Polypeptide comprising repeated cell-adhesive core sequences
US5110604A (en) 1988-06-30 1992-05-05 Collagen Corporation Processes for producing collagen matrixes and methods of using same
US5126141A (en) 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
US5550187A (en) 1988-11-21 1996-08-27 Collagen Corporation Method of preparing crosslinked biomaterial compositions for use in tissue augmentation
US5629291A (en) 1992-01-31 1997-05-13 La Jolla Cancer Research Foundation Methods of modulating fibronectin extracellular matrix assembly
US5292514A (en) 1992-06-24 1994-03-08 Minnesota Mining And Manufacturing Company Azlactone-functional substrates, corneal prostheses, and manufacture and use thereof
US5670483A (en) 1992-12-28 1997-09-23 Massachusetts Insititute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US5955343A (en) 1992-12-28 1999-09-21 Massachusetts Institute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
GB2274988A (en) 1993-02-10 1994-08-17 Mcconn Stern Rita Iodine containing wound-healing preparations
US5709854A (en) 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5773577A (en) 1994-03-03 1998-06-30 Protein Polymer Technologies Products comprising substrates capable of enzymatic cross-linking
US5527610A (en) 1994-05-20 1996-06-18 The Uab Research Foundation Elastomeric polypeptide matrices for preventing adhesion of biological materials
US5510102A (en) 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
WO1996040033A1 (en) 1995-06-07 1996-12-19 Clarion Pharmaceuticals Inc. Non-biological patch for hemostasis
WO1996040961A1 (en) 1995-06-07 1996-12-19 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
HUP9903586A3 (en) 1996-04-04 2003-02-28 Baxter Ag Hemostatic sponge based on collagen
US6489446B1 (en) 1996-08-07 2002-12-03 Hsc Research And Development Limited Partnership Self-aligning peptides modeled on human elastin and other fibrous proteins
WO1998030141A2 (en) 1997-01-09 1998-07-16 Cohesion Technologies, Inc. Devices for tissue repair and methods for preparation and use thereof
US6224893B1 (en) 1997-04-11 2001-05-01 Massachusetts Institute Of Technology Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering
US6428811B1 (en) 1998-03-11 2002-08-06 Wm. Marsh Rice University Temperature-sensitive polymer/nanoshell composites for photothermally modulated drug delivery
US6046160A (en) 1999-07-22 2000-04-04 Deroyal Industries, Inc. Composition and method for enhancing wound healing
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
US20020132274A1 (en) 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
PL206194B1 (pl) 2001-01-25 2010-07-30 Nycomed Pharma Asnycomed Pharma As Sposób wytwarzania zawiesiny cząstek fibrynogenu i trombiny, zawiesina zawierająca fibrynogen, trombinę i alkohol oraz sposób powlekania nośnika taką zawiesiną
WO2002062969A2 (en) 2001-02-06 2002-08-15 Massachusetts Institute Of Technology Cellular reprogramming in peptide hydrogel and uses thereof
US7449180B2 (en) 2001-02-06 2008-11-11 John Kisiday Macroscopic scaffold containing amphiphilic peptides encapsulating cells
US7179784B2 (en) 2001-07-10 2007-02-20 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
AU2003222167A1 (en) 2002-04-02 2003-10-20 Northwestern University Peptide amphiphile solutions and self assembled peptide nanofiber networks
AU2003241335A1 (en) 2002-05-09 2003-11-11 The Regents Of The University Of California Method of analyzing ataxia-telangiectasia protein
US20040242469A1 (en) 2002-05-13 2004-12-02 Lee Richard T. Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof
GB0216286D0 (en) 2002-07-15 2002-08-21 Univ Leeds Network
JP2005534697A (ja) 2002-08-06 2005-11-17 エピックス ファーマシューティカルズ, インコーポレイテッド ペプチド凝集体
WO2005014615A2 (en) 2003-06-25 2005-02-17 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
US7713923B2 (en) 2003-06-25 2010-05-11 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
GB0404374D0 (en) 2004-02-27 2004-03-31 Univ Manchester Treatment of bacterial infections
CA2572964C (en) 2004-07-06 2018-03-06 3D Matrix, Inc. Purified amphiphilic peptide compositions and uses thereof
AU2005323062A1 (en) 2005-01-04 2006-07-13 The Brigham And Women's Hospital, Inc. Sustained delivery of PDGF using self-assembling peptide nanofibers
US9162005B2 (en) 2005-04-25 2015-10-20 Arch Biosurgery, Inc. Compositions for prevention of adhesions and other barrier applications
KR20100102750A (ko) 2005-04-25 2010-09-24 메사추세츠 인스티튜트 오브 테크놀로지 지혈 및 다른 생리학적 활성을 촉진하기 위한 조성물 및 방법
JP4982841B2 (ja) 2005-10-12 2012-07-25 国立大学法人名古屋大学 再生医療骨組成物
US8796544B2 (en) 2005-12-14 2014-08-05 Massachusetts Institute Of Technology Bio-sensitized solar cells (BSSC)
HUE037994T2 (hu) 2006-04-25 2018-09-28 Massachusetts Inst Technology Készítmények és eljárások szennyezõ anyagok, testfolyadékok vagy más anyagok mozgásának befolyásolására és/vagy más fiziológiai állapotok befolyásolására
EP2066697A2 (en) 2006-09-26 2009-06-10 Massachusetts Institute of Technology Modified self-assembling peptides
JP5558104B2 (ja) 2006-12-11 2014-07-23 スリー−ディー マトリックス, インコーポレイテッド 心組織の保護および再生のための組成物および方法
US9415084B2 (en) 2007-03-14 2016-08-16 Arch Biosurgery, Inc. Treatment of leaky or damaged tight junctions and enhancing extracellular matrix
WO2008136820A1 (en) 2007-05-01 2008-11-13 Massachusetts Institute Of Technology Stabilization of mammalian membrane proteins by short surfactant peptides
US20090069547A1 (en) 2007-05-01 2009-03-12 Massachusetts Institute Of Technology Stabilization of mammalian membrane proteins by short surfactant peptides
WO2009018467A2 (en) 2007-07-31 2009-02-05 Massachusetts Institute Of Technology Bio-sensing nanodevice
WO2010014903A1 (en) 2008-07-31 2010-02-04 Massachusetts Institute Of Technology Multiplexed olfactory receptor-based microsurface plasmon polariton detector
ES2491565T3 (es) 2008-08-27 2014-09-08 3-D Matrix, Ltd. Agente de transfección
CN105435211A (zh) 2008-10-06 2016-03-30 三维肽胶株式会社 组织闭塞剂
CN101514225B (zh) 2008-10-13 2011-09-14 西安蓝晶生物科技有限公司 自聚体多肽及其制备方法和应用
JP2010222338A (ja) * 2009-02-27 2010-10-07 Three D Matrix:Kk 核酸移送担体
US8999300B2 (en) * 2009-10-26 2015-04-07 Nissan Chemical Industries Ltd. Cosmetic, external skin preparation, and medical instrument
WO2011072482A1 (en) 2009-12-14 2011-06-23 The University Of Hong Kong Nano cancer barrier device(ncbd) to immobilize and inhibit the division of metastic cancer stem cells
JP2011126855A (ja) 2009-12-15 2011-06-30 Three D Matrix:Kk タンパク質の凝集抑制剤
US20130236891A1 (en) 2010-08-20 2013-09-12 3-D Matrix, Ltd. Method and composition for the treatment, prevention, and diagnosis of cancer containing or derived from cancer stem cells
US9149511B2 (en) 2011-06-30 2015-10-06 Ethicon, Inc. Procoagulant peptides and their derivatives and uses therefor
EP2854778A4 (en) 2012-05-31 2016-03-30 Massachusetts Inst Technology DELAYED RELEASE OF MOLECULES USING PEPTIDTENSIDES AND USES THEREOF
GB2503701B (en) 2012-07-04 2015-08-26 Shameem Anthony Carl Sampath Limb exercise device
EP2869903B1 (en) 2012-07-06 2018-11-28 3-D Matrix Ltd. Fill-finish process for peptide solutions
US9140677B2 (en) 2012-08-13 2015-09-22 Massachusetts Institute Of Technology Methods and apparatus for artificial olfaction
HK1220116A1 (zh) 2013-03-06 2017-04-28 3-D Matrix Ltd. 使用纯化的两亲性多肽组合物的外科手术方法
WO2015027203A1 (en) 2013-08-22 2015-02-26 Arch Biosurgery, Inc. Implantable meshes for controlling the movement of fluids
ES2712608T3 (es) 2014-03-10 2019-05-14 3 D Matrix Ltd Péptidos autoensamblantes para el tratamiento de las bullas pulmonares
WO2015138475A1 (en) 2014-03-10 2015-09-17 3-D Matrix, Ltd. Self-assembling peptides as bronchial obstruction agents
ES3037364T3 (en) 2014-03-10 2025-10-01 3 D Matrix Ltd Sterilization and filtration of peptide compositions
JP2017513927A (ja) 2014-03-10 2017-06-01 株式会社スリー・ディー・マトリックス 肺の漏出を治療するための自発組織化ペプチド
DK3116896T3 (en) 2014-03-10 2019-03-18 3 D Matrix Ltd SELF-PREPARING PEPTIME COMPOSITIONS
PL229030B1 (pl) 2014-03-13 2018-05-30 Zygmunt Jerzy Szymański Nanopreparat bakteriobójczy
JP2014208669A (ja) 2014-06-17 2014-11-06 株式会社スリー・ディー・マトリックス タンパク質の凝集抑制剤
JP2016028102A (ja) 2015-10-21 2016-02-25 株式会社スリー・ディー・マトリックス タンパク質の凝集抑制剤
WO2017120092A1 (en) 2016-01-06 2017-07-13 3-D Matrix, Ltd. Combination compositions
JPWO2017164334A1 (ja) 2016-03-23 2019-02-28 公益財団法人川崎市産業振興財団 ホウ素クラスター結合ペプチド化合物
US10894088B2 (en) 2016-11-25 2021-01-19 National University Corporation Okayama University BSH complex for boron neutron capture therapy
KR20240158357A (ko) 2017-11-09 2024-11-04 가부시키가이샤 팜엑스 테라퓨틱스 miRNA를 포함하는 암 치료용 의약 조성물
CN117085140A (zh) 2017-12-15 2023-11-21 立美基股份有限公司 表面活性剂肽纳米结构及在药物递送中的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LANGMUIR, vol. 30, JPN6022053450, 2014, pages 10072 - 10079, ISSN: 0005069014 *
THE JOURNAL OF PHYSICAL CHEMISTRY B, vol. 118, JPN6022053447, 2014, pages 12215 - 12222, ISSN: 0005069013 *

Also Published As

Publication number Publication date
CN111712230B (zh) 2024-04-26
CN111712230A (zh) 2020-09-25
US12239744B2 (en) 2025-03-04
US20220249392A1 (en) 2022-08-11
JP7760174B2 (ja) 2025-10-27
CN117085140A (zh) 2023-11-21
US11324703B2 (en) 2022-05-10
JP2025028940A (ja) 2025-03-05
US20190231706A1 (en) 2019-08-01
WO2019116092A1 (en) 2019-06-20
IL275380A (en) 2020-07-30
EP3723726A1 (en) 2020-10-21
JP2023076699A (ja) 2023-06-01

Similar Documents

Publication Publication Date Title
JP7760174B2 (ja) 界面活性ペプチドナノ構造および薬物送達における使用
EP2956119B1 (en) Nanoparticle delivery compositions
US12195558B2 (en) Targeted delivery system and methods of use therefor
JP2001512739A (ja) 抗生作用ペプチドから誘導される線状ペプチド、製法および活性物質を仲介する用途
US20110262347A1 (en) Methods and compositions for enhanced delivery of compounds
Breger et al. Nanoparticle cellular uptake by dendritic wedge peptides: achieving single peptide facilitated delivery
Kozhikhova et al. A novel peptide dendrimer LTP efficiently facilitates transfection of mammalian cells
CA2290071A1 (en) Peptides which enhance transport of an active agent across tissues and compositions and methods of using the same
WO2012112767A2 (en) Collagen-targeted nanoparticles
WO2016019872A1 (zh) 核酸载体、其制备方法及用途
WO2018106273A1 (en) Collagen targeting nanofibers and nanosheets
Schuster et al. S-layer proteins as key components of a versatile molecular construction kit for biomedical nanotechnology
WO2015057820A2 (en) Peptide constructs and well-defined aggregates thereof
Krishnakumari et al. Escherichia coli lipopolysaccharide modulates biological activities of human-β-defensin analogues but not non-ribosomally synthesized peptides
Gonzalez-Mariscal et al. Inventions designed to enhance drug delivery across epithelial and endothelial cells through the paracellular pathway
WO2005092389A1 (ja) 複合粒子および被覆複合粒子
US8883989B2 (en) Fractalkine binding polynucleotides and methods of use
Kah et al. Nanoparticle Interface to biology: applications in probing and modulating biological processes
JP5499296B2 (ja) 細胞の吸着を制御可能なポリペプチド
JP2008031142A (ja) 脂肪組織標的化ペプチド及び該ペプチドを有するリポソーム
Skyttner Peptide-Liposome Model Systems for Triggered Release
Fitzkee et al. How do nanoparticle size and protein charge affect gold nanoparticle-protein interactions?
US10458979B2 (en) Solid supported artificial cell membrane system
WO2023014293A2 (en) A ph-responsive composition for facilitating delivery of a cargo and a method of encapsulating cargo with a ph-responsive composition
Moghal Elementary processes and rate of entry of transportan 10 into single vesicle lumen and their membrane potential dependence

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230406

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230529